TRIDENTE
What it tests: Rechallenge with encorafenib + binimetinib + cetuximab in BRAF V600E-mutant metastatic colorectal cancer
The week in oncology, in your inbox
The OncoAlert Newsletter goes to 10,000+ oncologists and cancer stakeholders: every week, and every day during the major congresses. Free, independent, GDPR-compliant and easy to leave.